Expert Interview
Discussing the clinical data for 4D-150 and the design of the 4FRONT Phase 3 program presented at the 4D-150 Wet AMD Development Day.
Ticker(s): FDMTInstitution: Rush University & Illinois Retina Associates
- Assistant Professor of Ophthalmology at Rush University Medical Center & co-investigator on several clinical trials.
- Manages 20 patints a week with wAMD.
- Research interests include assessing the color performance of the NGENUITY 3D visualization system and meta-analyses of cytokines in various retinal diseases; clinical focus on the medical and surgical treatment of diseases affecting the retina, vitreous and macula.
Roughly how many patients do you manage for Wet AMD?
Added By: nikki_adminHow familiar are you with the recent Phase 3 data for 4D-150?
Added By: nikki_adminCan you provide background information about yourself, your area of expertise, and details about your current practice setting, including how many wet AMD patients you manage monthly?
Added By: catalin_adminCan you explain your current standard of care and available medical options for wet AMD patients?
Added By: catalin_adminHow do you compare 4D Molecular's gene therapy to Regenx, and would you say 4D is leading in the gene therapy space, especially with their progress toward Phase 3 studies?
Added By: catalin_adminWhat are your thoughts on the Phase 3 trial design for 4D’s gene therapy, and how does it compare to other ongoing trials like those for TKIs?
Added By: catalin_adminOn a scale of 1 to 10, how would you rank your excitement about these gene therapies, considering the safety, long-term potential, and upcoming innovations?
Added By: catalin_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
